gemcitabine / Generic mfg. - LARVOL DELTA

RASolute 302: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P3 | N=501 | Active, not recruiting | Sponsor: Revolution Medicines, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Optim.AI™ 2.0: Functional precision platform for identifying effective immunotherapy combinations in DLBCL (ASH 2025) - "PBMCs were added to tumor cells at a fixed effector-to-target ratio, and Optim.AI 2.0 combinatorial drug sensitivity testing plates were applied to the co-culture system, with up to 12 FDA-approved drugs, including monoclonal antibodies (rituximab, obinutuzumab), antibody-drug conjugates (polatuzumab), bispecific antibodies (epcoritamab, glofitamab), targeted small-molecule inhibitors (venetoclax, everolimus, zanubrutinib), and cytotoxic chemotherapies (gemcitabine, oxaliplatin, cyclophosphamide, doxorubicin). This study demonstrates the feasibility of Optim.AI™ 2.0, an enhanced co-culture-based platform which provides a physiologically relevant and scalable approach to functionally evaluate immunotherapy drug sets. With further validation, Optim.AI™ 2.0 holds strong potential to support clinical decision-making and expand the use of immunotherapies in DLBCL."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Sarcoma • Solid Tumor

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma (ASH 2025) - " Pts with R/R NHL who underwent leukapheresis received pre-treatment with obinutuzumab prior to the first dose of glofitamab. Based on disease progression status, pts received glofitamab monotherapy or glofitamab combined with gemcitabine + oxaliplatin/ BTK inhibitor/ methotrexate regimens prior to CAR-T infusion... Glofitamab bridging therapy prior to CAR-T demonstrated promising efficacy in pts with high-risk NHL, without significant safety concerns or detrimental impact on CAR-T cell kinetics. This study provides preliminary evidence for redefining therapeutic paradigms in non-Hodgkin lymphoma, particularly PCNSL, supporting further investigation through expanded validation cohorts and longitudinal outcomes assessment."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • TP53

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia (ASH 2025) - P2 | "These findings provide a strong rationale for combining ruxolitinib with P-Gemox (pegaspargase, gemcitabine, and oxaliplatin) to improve outcomes in ANKL. This regimen appears to be an effective and well-tolerated induction strategy while bridging to allo-HSCT. These preliminary findings warrant further evaluation in larger, prospective studies."

Clinical • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Fibrosis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Influenza • Leukemia • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience (ASH 2025) - "G-CSF and Plerixafor-mobilized peripheral blood stem cell were used in all patients...Eligible patients received agents like Rituximab, Brentuximab, and Nivolumab with additional cost per cycle...The regimen's daycare feasibility and reduced hospitalization needs offer significant quality-of-life and economic advantages. Substituting Carboplatin for Cisplatin further enhances administration convenience."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Transplantation

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Haematological toxicities with targeted drugs in tumors: A systematic review and network meta-analysis of randomized controlled trials (ASH 2025) - "1 patient treated with sorafenib plus chemotherapy was reported to have died as a result of pancytopenia and 1 patient treated with chemotherapy (gemcitabine plus cisplatin) died due to anemia. Our study confirmed that chemotherapy with or without a placebo, one targeted drug with chemotherapy was associated with more severe hematologic toxicities compared with the use of one targeted drug, tepotinib plus gefitinib, tivantinib plus erlotinib. In the targeted drug monotherapy category, for the primary outcome, we found that alectinib and gefitinib had a higher risk of all-grade (grade 1-5) and severe-grade (grade 3-5) anemia, respectively...Ganitumab plus chemotherapy had the highest risk of grade 1-5 anemia and thrombocytopenia. Afatinib plus chemotherapy had the highest risk of grade 3-5 anemia and thrombocytopenia. Ramucirumab plus chemotherapy had the highest risk of grade 1-5 and 3-5 neutropenia. Veliparib plus chemotherapy had the highest risk of grade 1-5 and 3-5..."

Retrospective data • Review • Febrile Neutropenia • Leukopenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO (ASH 2025) - P3 | "We report updated efficacy and safety of Glofit-GemOxversus R-GemOx, with 3 years of follow-up, in patients with R/R DLBCL after ≥1 prior line of therapy (LOT)from the global Phase III STARGLO trial (NCT04408638).MethodsPatients were randomized 2:1 to either Glofit-GemOx (8 cycles plus 4 cycles glofitamab monotherapy) orR-GemOx (8 cycles) and stratified by number of prior LOT (1 vs ≥2) and refractoriness to last therapy.Following obinutuzumab pretreatment, glofitamab was given in Cycle 1 as weekly step-up doses(2.5/10mg), then 30mg target dose every 21 days from Cycle 2 Day 1. The safety profile remained consistent with the known risks of each study drug and wasmanageable. This updated analysis demonstrates the sustained remission and continued survivaladvantages that fixed-duration Glofit-GemOx offers for patients with R/R DLBCL."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy (ASH 2025) - P3 | "In SUNMO, Mosun-Pola provided benefits across multiple aspects of HRQoL compared withR-GemOx, particularly in maintaining/improving physical functioning, fatigue, lymphoma symptoms, andPN. Pts treated with Mosun-Pola achieved clinically meaningful improvements in PROs, with scoresexceeding the MCID in several domains and exhibiting a delay in deterioration of >1 year for physicalfunctioning, and >2 months for PN and lymphoma symptoms. Improved PROs with Mosun-Pola vs R-GemOx suggest benefits in HRQoL with chemotherapy-free bispecific antibody combinations."

Clinical • HEOR • B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Gynecologic Cancers • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral Neuropathic Pain

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study (ASH 2025) - "The combination of Lipo-MIT with R-GDP demonstrated encouraging efficacy and a manageable safetyprofile in patients with R/R DLBCL. Further studies with continued follow-up are warranted to assesssurvival outcomes."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study (ASH 2025) - P2 | "We previously investigated the efficacy of CD-R-GemOx, a dual epigenetic agent-primed immunochemotherapy regimen, consisting of chidamide,decitabine, rituximab, gemcitabine, and oxaliplatin, in this high-risk population...This emphasizes thecritical need to optimize the dual epigenetic immunochemotherapy approach to enhance patientoutcomes while mitigating adverse effects.Aims: This study aims to evaluate the efficacy and safety of a modified dual epigenetic primingimmunochemotherapy regimen, termed CAGM, consisting of chidamide, azacitidine, obinutuzumab, andmitoxantrone liposome, in R/R DLBCL patients who had failed salvage therapy. This ongoing, prospective, multicenter, open-label phase II study (NCT05823701) enrolledpatients with R/R DLBCL who had failed salvage therapy... This study demonstrates the favorable efficacy and significantly lower hematologicaltoxicities of the CAGM regimen in R/R DLBCL patients, offering a promising therapeutic option for..."

Clinical • P2 data • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Infectious Disease • Lymphoma • Mucositis • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Propensity score matched comparison of outcomes following treatment with pola-R-CHP versus R-CHOP for diffuse large B cell lymphoma patients captured in a real-world database (ASH 2025) - "Outcomeswere assessed over a one year (1yr) window starting one day after treatment initiation and includedchemotherapy-related toxicities, treatment with standard second-line therapy (axicabtagene ciloleucel,lisocabtagene maraleucel, tafasitamab or gemcitabine for all patients, as well as Pola for R-CHOPpatients) as a surrogate for disease free survival, and mortality. 1476 patients treated with R-CHOP and 421 patients treated with Pola-R-CHP were identified and421 patients per treatment group were analyzed after propensity score matching was performed. In this large real-world analysis of US patients with DLBCL treated with R-CHOP or Pola-R-CHP incorporating propensity score matching, key toxicity outcomes were similar. While survival at 1yrwas similar between cohorts, patients treated with R-CHOP were more likely to receive second-linetherapy within 1yr of treatment initiation as compared to patients treated with Pola-R-CHOP. As patientstreated with R-CHOP followed..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetes • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Renal Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia • Type 2 Diabetes Mellitus

Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study (ASH 2025) - P1/2 | "Lipo-MIT combined with GDP (MGDP) regimen demonstrated promising efficacy andmanageable safety in r/r PTCL, warranting further investigation."

Clinical • P1/2 data • Follicular Lymphoma • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • ALK

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma (ASH 2025) - P2 | "Moreover,severe short- and long-term side effects remain major concerns.Recent studies suggest high response rates of up to 95% and unprecedented progression-free survival(PFS) with anti-programmed cell death protein 1 (PD-1)-based salvage regimens such as pembrolizumab,gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD)...Initiatedin March 2024 at four German centers, the trial has enrolled 23 patients to date.Patients receive an initial cycle of pembrolizumab followed by two cycles of P-ICE (pembrolizumab,ifosfamide, carboplatin, etoposide). After PET restaging, complete responders continue with two morecycles of P-ICE, while patients failing to achieve a complete response switch to two cycles of P-DHAP(pembrolizumab, dexamethasone, high-dose cytarabine, cisplatin)...The interim analysis of the Pembro-CORE trial demonstrates promising early results for a PET-adapted,HD-CT-free treatment strategy in first-relapsed cHL. A high CMR of 93.3% was observed among..."

P2 data • Acute Kidney Injury • Classical Hodgkin Lymphoma • Dermatitis • Dermatology • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Renal Disease • Respiratory Diseases

Nivolumab and pembrolizumab in treatment of relapsed or refractory classical Hodgkin lymphoma: Systematic review and meta-analysis of clinical trials (ASH 2025) - "Managementinvolves platinum/gemcitabine-based chemotherapy, brentuximab vedotin (BV), autologous stem celltransplant (ASCT), or PD-1 inhibitors that have led to improved outcomes in the past decade...Nivolumab andpembrolizumab monotherapies were investigated in 5 and 3 trials, respectively; BV with nivolumab wasstudied in 2 trials, the rest of the studies evaluated different combinations of immune-chemotherapies(n=2) or different immunotherapies (n=4), such as ipilimumab (±BV) and lirilumab... This meta-analysis confirms that both pembrolizumab and nivolumab in the treatment ofr/r cHL similarly improve clinical outcomes with an acceptable safety profile. As the treatment landscapeof r/r cHL evolves and with the Introduction of PD-1 inhibitors in the frontline setting, the efficacy of theseagents in combination with other treatment modalities, including emerging immunotherapeutic agents,should be investigated. Patients with multiple comorbidities, prior..."

Retrospective data • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor) (ASH 2025) - "Pts had a median 2 prior lines of therapy (LOT), 60% had primary refractorydisease, 53% had prior CART, and 4 received gemcitabine/oxaliplatin with BsAb...CRS was treated with steroids (n=8) and tocilizumab (n=11)...Future analysisof a larger pt cohort is needed to validate this finding. Our study supports the utilization of a RDES forglofit or epco when clinically warranted."

Clinical • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003 (ASH 2025) - P2/3 | "The phase 2/3 waveLINE-003 trial (NCT05139017) evaluated the safety and efficacy of ZV plusrituximab and gemcitabine-oxaliplatin (R-GemOx) in participants with R/R DLBCL...The median number of prior therapies was 2.0 with 7 (18%) pts receiving prior CAR-T, 7 (18%)receiving prior ASCT, and 2 (5%) received prior polatuzumab vedotin... After approximately 19 months of follow-up, ZV plus R-GemOX continues to demonstratepromising efficacy and acceptable safety in R/R DLBCL at the RP2D of ZV of 1.75 mg/kg plus R-GemOx. Nonew safety concerns were reported. The efficacy expansion phase of this trial randomizing participants toZV plus R-GemOx versus R-GemOx is currently ongoing."

P2/3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Septic Shock • ROR1

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups (ASH 2025) - P3 | "Glofit-GemOx demonstrated superior survival and response outcomes vs R-GemOx,regardless of prior LOT and age, particularly in the 2L setting including in pts with primary refractorydisease and early relapse. Safety was generally consistent in pt subgroups vs the overall population andin line with prior results."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population (ASH 2025) - P1/2 | "In R/RDLBCL, standard salvage therapy with gemcitabine plus oxaliplatin (GemOx) yielded a complete response(CR) rate of 25%, overall response rate (ORR) of 41%, median progression-free survival (mPFS) of 3.6 mo,and median overall survival (mOS) of 12.9 mo (Abramson JS, et al. Epcor + GemOx demonstrated sustained remissions of >2 y, prolonged PFS and OS, anddeep MRD negativity in challenging-to-treat 2L+ R/R DLBCL; these results are widely applicable to adiverse pt population across the US and Europe. With longer follow-up, the safety profile remainedconsistent with previous reports. These findings support the combinability of epcor with standard-of-carechemotherapy and offer an effective option for ASCT-ineligible pts, a population with otherwise limited txchoices."

Clinical • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Pancreatic Adenocarcinoma • Pancreatic Cancer • Respiratory Diseases

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL (ASH 2025) - "The median number ofprior treatment lines before bridging therapy was 2 (range 1-4).Bridging therapy consisted of glofitamab monotherapy (3 patients) or glofitamab combined withchemotherapy (GVM [gemcitabine, vinorelbine, mitoxantrone hydrochloride liposome] in 4patients; GemOx [gemcitabine, oxaliplatin] in 4 patients). These preliminary data suggest that BsAbs-containing bridging therapy prior toCD19-specific CAR-T therapy, either alone or combined with HDT/ASCT, is effective and safe inDLBCL. More detailed data will be presented at the conference."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • TP53

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US) (ASH 2025) - "NCCN guidelines also now recommends the use ofglofitamab, in combination with gemcitabine and oxaliplatin (GemOx), for patients ineligible for CAR Tand ASCT in R/R 2L DLBCL. In the recent phase III trial involving patients with R/R DLBCL who wereineligible for ASCT, another BsAb mosunetuzumab, in combination with polatuzumab vedotin (mosun-pola), led to significantly higher overall response rates and showed a trend toward improvement in bothprogression-free and overall survival compared to rituximab in combination with GemOx (Westin et al.ICML 2025)... Our findings suggest that patients with relapsed/refractory DLBCL experience improvedsurvival outcomes when treated with CAR T-cell therapy, reinforcing its designation as a category 1recommendation by the NCCN. While adherence to these guidelines is associated with better outcomes,clinical or logistical factors may understandably limit the ability to follow recommended treatmentpathways at times. Nonetheless, the analysis..."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies (ASH 2025) - "Supportive care with 500 ml intravenous fluids,dexamethasone (dex) 16 mg, acetaminophen 650 mg, and diphenhydramine 50 mg was administered 30-120 minutes prior to each epco injection, including through the completion of cycle (C) 1...Three pts received epco incombination with gemcitabine and oxalipatin...CRS was treated with tocilizumab (toci) alone in all 3 pts... We report a standardized process with enhanced supportive care in C1 for a rapid doseescalation of epco, enabling pts to achieve the 1st full therapeutic dose on D 7. This approach hasdemonstrated feasibility and safety. All CRS events were low grade and resolved quickly."

Clinical • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology